- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | PharmaLegacy acquires BTS Research in hopes of becoming a 'highly competitive global CRO' | ||
| Mo | ESMO: Exact Sciences shows off early colorectal cancer blood test data | ||
| Mo | Amgen and Merck become first industry partners of academic clinical trial diversity initiative | ||
| Mo | Novo Nordisk's latest RNA deal involves $530M biobucks to sing in Korro's opera | ||
| Mo | ESMO: Lantheus' phase 3 radiotherapy readout not enough to topple Pluvicto, say analysts | ||
| Mo | Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor | ||
| Mo | ESMO: Bristol Myers axes Immatics' bispecific after $150M bet | ||
| Fr | Eli Lilly sells Life Sciences Studio lab to Arctoris, moving automation platform from San Diego to Oxford | ||
| Fr | Medtronic appoints new chief medical officer for digital surgery and robotics | ||
| Fr | Biolexis enters oral GLP-1 horse race with preclinical study showing small molecule reduced weight of obese mice | ||
| Fr | Atea finally gives up COVID ambitions after antiviral fails to reduce hospitalizations, deaths in phase 3 | ||
| Fr | Neurocrine's bid to save schizophrenia prospect fails | ||
| Fr | Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs | ||
| Fr | FDA pushed to be more open, collaborative to accelerate rare disease R&D | ||
| Do | In wake of Q2 revenue drop, Charles River cuts 3% of workforce | ||
| Do | Chutes & Ladders-Cue Biopharma queues up J&J vet as CBO | ||
| Do | FDA greenlights over-the-counter hearing aid features for Apple's AirPods | ||
| Do | Inflammatix collects $57M as it awaits FDA review of infectious disease test | ||
| Do | Oncternal folds all clinical trials after lackluster data drop, patient death | ||
| Do | Sanofi's $80M bet on Fulcrum's dystrophy drug ends in phase 3 failure after 4 months | ||
| Do | Moderna targets $1.1B in R&D spending cuts, drops 5 programs amid profitability pressures | ||
| Do | F2G raises $100M to fund 2nd attempt to get new antifungal class to market | ||
| Do | Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis | ||
| Do | GSK's mRNA flu vaccine finally overcomes tricky B strains in phase 2 trial | ||
| Mi | Intercept's Ocaliva approval in jeopardy after FDA flags concerns in advisory committee briefing doc |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
